200,000+ products from a single source!
sales@angenechem.com
121569-61-7 | 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3S,9S,10R,11R,13R)-
CAS No: 121569-61-7 Catalog No: AG0015A6 MDL No:
Product Description
Catalog Number:
AG0015A6
Chemical Name:
9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methylamino)-, (3S,9S,10R,11R,13R)-
CAS Number:
121569-61-7
Molecular Formula:
C28H26N4O4
Molecular Weight:
482.5304
IUPAC Name:
18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
InChI:
InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)
InChI Key:
PBCZSGKMGDDXIJ-UHFFFAOYSA-N
SMILES:
CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O
Properties
Complexity:
935
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
482.195g/mol
Formal Charge:
0
Heavy Atom Count:
36
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
482.54g/mol
Monoisotopic Mass:
482.195g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
89.7A^2
Undefined Atom Stereocenter Count:
5
Undefined Bond Stereocenter Count:
0
XLogP3:
2.7
Literature
| Title | Journal |
|---|---|
| ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway. | The Journal of biological chemistry 20120706 |
| Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines. | International journal of radiation oncology, biology, physics 20120701 |
| Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe. | Molecular cancer research : MCR 20120501 |
| Chk'ing p53-deficient breast cancers. | The Journal of clinical investigation 20120402 |
| Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. | The Journal of clinical investigation 20120402 |
| A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. | Investigational new drugs 20120401 |
| ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity. | DNA repair 20120301 |
| Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. | Molecular cancer therapeutics 20120201 |
| Roles of phosphoinositide-dependent kinase-1 in α1B-adrenoceptor phosphorylation and desensitization. | European journal of pharmacology 20120115 |
| Bone morphogenetic protein (BMP)-4 and BMP-7 suppress granulosa cell apoptosis via different pathways: BMP-4 via PI3K/PDK-1/Akt and BMP-7 via PI3K/PDK-1/PKC. | Biochemical and biophysical research communications 20120113 |
| Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. | Leukemia & lymphoma 20111201 |
| M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. | Biochemical pharmacology 20111201 |
| Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. | Cell cycle (Georgetown, Tex.) 20111201 |
| Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. | Cardiovascular research 20111101 |
| Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110901 |
| A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. | Cancer chemotherapy and pharmacology 20110601 |
| Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules. | ACS chemical biology 20110520 |
| Chk1 has an essential role in the survival of differentiated cortical neurons in the absence of DNA damage. | Apoptosis : an international journal on programmed cell death 20110501 |
| Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01. | Molecular cancer therapeutics 20110501 |
| The DNA damage effector Chk1 kinase regulates Cdc14B nucleolar shuttling during cell cycle progression. | Cell cycle (Georgetown, Tex.) 20110215 |
| Phosphorylated hMSH6: DNA mismatch versus DNA damage recognition. | Mutation research 20110110 |
| Protein kinase C βII and δ/θ play critical roles in bone morphogenic protein-4-stimulated osteoblastic differentiation of MC3T3-E1 cells. | Biochemical and biophysical research communications 20101203 |
| Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. | Molecular pharmacology 20101101 |
| PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. | Molecular cancer therapeutics 20101101 |
| Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells. | Anticancer research 20101001 |
| p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors. | Cell proliferation 20100801 |
| Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors. | Journal of molecular modeling 20100701 |
| Targeting slow-proliferating ovarian cancer cells. | International journal of cancer 20100515 |
| Cadmium-induced DNA damage triggers G(2)/M arrest via chk1/2 and cdc2 in p53-deficient kidney proximal tubule cells. | American journal of physiology. Renal physiology 20100201 |
| A role for Chk2 in DNA damage induced mitotic delays in human colorectal cancer cells. | Cell cycle (Georgetown, Tex.) 20100115 |
| A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. | Cancer chemotherapy and pharmacology 20100101 |
| Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. | Cancer research 20091115 |
| Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response. | Radiation research 20091101 |
| Interaction with checkpoint kinase 1 modulates the recruitment of nucleophosmin to chromatin. | Journal of proteome research 20091001 |
| The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? | Cancer biology & therapy 20090801 |
| Cell cycle kinases as therapeutic targets for cancer. | Nature reviews. Drug discovery 20090701 |
| Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090301 |
| Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. | Blood 20080915 |
| Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. | Cell cycle (Georgetown, Tex.) 20080701 |
| G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. | Oncogene 20080619 |
| DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. | Cell cycle (Georgetown, Tex.) 20080601 |
| Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size. | International journal of pharmaceutics 20080303 |
| Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. | Cancer chemotherapy and pharmacology 20080301 |
| Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. | Molecular cancer therapeutics 20080301 |
| Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. | Molecular cancer therapeutics 20080201 |
| Increased inducible nitric oxide synthase in lung carcinoma of smokers. | Cancer 20080115 |
| p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest. | Radiation research 20071201 |
| AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. | Cancer letters 20071108 |
| MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. | Blood 20070915 |
| UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. | Gynecologic oncology 20070801 |
| Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. | Blood 20070515 |
| Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070501 |
| Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. | Molecular cancer therapeutics 20070501 |
| [Research on cyclin-dependent kinase inhibitors: state of the art and perspective]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070501 |
| UCN-01 (7-hydroxystaurosporine) induces apoptosis and G1 arrest of both primary and metastatic oral cancer cell lines in vitro. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20070301 |
| p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. | Cancer cell 20070201 |
| 7-Hydroxystaurosporine may have a therapeutic role in treatment-resistant depression by inhibition of calcium/calmodulin-dependent protein kinase II. | Medical hypotheses 20070101 |
| Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. | Cancer research 20070101 |
| Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. | Molecular pharmacology 20061201 |
| Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). | Clinical cancer research : an official journal of the American Association for Cancer Research 20061201 |
| The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25A/Cdk2-independent mechanism. | The Journal of biological chemistry 20061013 |
| Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. | British journal of cancer 20060522 |
| p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. | Oncogene 20060511 |
| On the observed large interspecies overprediction of human clearance ('vertical allometry') of UCN-01: further support for a proposed model based on plasma protein binding. | Journal of clinical pharmacology 20060401 |
| Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. | Molecular and cellular biology 20060401 |
| Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. | Blood 20060315 |
| Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. | Annals of oncology : official journal of the European Society for Medical Oncology 20060201 |
| Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. | Cancer biology & therapy 20051101 |
| Two targets are better than one. Promising combination therapy to treat breast cancer. | Cancer biology & therapy 20051101 |
| A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. | Investigational new drugs 20050801 |
| Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. | Cancer research 20050801 |
| Reducing the impact of binding of UCN-01 to human alpha1-acid glycoprotein by encapsulation in liposomes. | Biological & pharmaceutical bulletin 20050701 |
| The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050615 |
| The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050615 |
| Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. | Oncogene 20050526 |
| Drugging cell cycle kinases in cancer therapy. | Current drug targets 20050501 |
| Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. | Cancer research 20050415 |
| Review of UCN-01 development: a lesson in the importance of clinical pharmacology. | Journal of clinical pharmacology 20050401 |
| Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration. | Acta pharmacologica Sinica 20050401 |
| RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. | Cancer research 20050401 |
| Indifferently pursued or unowned drugs: who should lead where companies do not tread? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320 |
| Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320 |
| Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. | Molecular cancer therapeutics 20050301 |
| Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. | Blood 20050215 |
| The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. | The Journal of biological chemistry 20050211 |
| Synergistic stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage differentiation in HL-60 and HL-525 human myeloid leukemia cells. | International journal of oncology 20050201 |
| A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050115 |
| Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha1-acid glycoprotein. | The Journal of biological chemistry 20050114 |
| The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. | Oncogene 20050106 |
| Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. | Cell cycle (Georgetown, Tex.) 20050101 |
| [Abrogation effect of UCN-01 on radiation-induced G2 phase arrest of tumor cells and its mechanism]. | Ai zheng = Aizheng = Chinese journal of cancer 20050101 |
| Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01. | Anticancer research 20050101 |
| Inhibitors of cyclin-dependent kinase modulators for cancer therapy. | Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20050101 |
| Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. | Radiation research 20041201 |
| Chk1 versus Cdc25: chking one's levels of cellular proliferation. | Cell cycle (Georgetown, Tex.) 20041101 |
| 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041101 |
| Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041015 |
| The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. | Molecular cancer therapeutics 20041001 |
| Combinations of 5-fluorouracil with UCN-01 or staurosporine. | Nucleosides, nucleotides & nucleic acids 20041001 |
| Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01. | Journal of experimental therapeutics & oncology 20041001 |
| Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. | Cancer research 20040915 |
| CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. | Molecular cancer therapeutics 20040901 |
| Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein. | Pharmaceutical research 20040901 |
| UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines. | Journal of neurochemistry 20040801 |
| In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040801 |
| Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. | Cancer 20040701 |
| Rapid degradation of Cdt1 upon UV-induced DNA damage is mediated by SCFSkp2 complex. | The Journal of biological chemistry 20040625 |
| Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040615 |
| Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. | Acta pharmacologica Sinica 20040601 |
| Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. | Genes & development 20040601 |
| UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. | Cancer research 20040515 |
| Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. | Oncology reports 20040501 |
| Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. | Blood 20040401 |
| Pheophorbide a is a specific probe for ABCG2 function and inhibition. | Cancer research 20040215 |
| Cell-cycle targeted therapies. | The Lancet. Oncology 20040101 |
| Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. | Molecular pharmacology 20031201 |
| The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. | European journal of biochemistry 20031201 |
| Induction by staurosporine of hepatocyte growth factor production in human skin fibroblasts independent of protein kinase inhibition. | Biochemical pharmacology 20031101 |
| Cell cycle modulators for the treatment of lung malignancies. | Clinical lung cancer 20031101 |
| Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. | The Biochemical journal 20031015 |
| Induction of colon cancer cell death by 7-hydroxystaurosporine (UCN-01) is associated with increased p38 MAPK and decreased Bcl-xL. | Anti-cancer drugs 20031001 |
| Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. | Blood 20030901 |
| An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells. | The Journal of biological chemistry 20030815 |
| Survival-signaling pathway as a promising target for cancer chemotherapy. | Cancer chemotherapy and pharmacology 20030701 |
| Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. | Cancer chemotherapy and pharmacology 20030701 |
| Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. | Cancer chemotherapy and pharmacology 20030401 |
| Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1. | The EMBO journal 20030203 |
| Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. | Molecular pharmacology 20030101 |
| [Abrogation of radiation-induced G2 arrest and radiosensitization by 7-hydroxystaurosporine (UCN-01) in human nasopharyngeal carcinoma cell line]. | Ai zheng = Aizheng = Chinese journal of cancer 20030101 |
| Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. | Current medicinal chemistry. Anti-cancer agents 20030101 |
| Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. | Current medicinal chemistry. Anti-cancer agents 20030101 |
| Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). | Oncology reports 20030101 |
| Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo. | Breast cancer (Tokyo, Japan) 20030101 |
| Structural basis for Chk1 inhibition by UCN-01. | The Journal of biological chemistry 20021129 |
| Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. | Blood 20021101 |
| Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). | Clinical cancer research : an official journal of the American Association for Cancer Research 20021101 |
| UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. | Cancer research 20021015 |
| A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. | Molecular cancer therapeutics 20021001 |
| Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. | Hematology/oncology clinics of North America 20021001 |
| Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. | Molecular pharmacology 20020901 |
| 7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism. | International journal of oncology 20020801 |
| Hematologic malignancies: new developments and future treatments. | Seminars in oncology 20020801 |
| Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines. | British journal of cancer 20020729 |
| Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. | The Journal of biological chemistry 20020719 |
| 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. | Radiation research 20020701 |
| 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. | Neurosurgery 20020601 |
| Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. | Leukemia & lymphoma 20020401 |
| Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). | Oncogene 20020307 |
| Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. | Neoplasia (New York, N.Y.) 20020301 |
| Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. | Anti-cancer drugs 20020301 |
| Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. | Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 20020201 |
| UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. | Molecular cancer therapeutics 20020201 |
| Protein kinase C inhibitors. | Current oncology reports 20020101 |
| Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. | Acta biochimica Polonica 20020101 |
| The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. | The oncologist 20020101 |
| UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction. | Breast cancer (Tokyo, Japan) 20020101 |
| Combining phorbol ester (PMA) with UCN-01: fueling fire with water. | Cell cycle (Georgetown, Tex.) 20020101 |
| UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937). | Cell cycle (Georgetown, Tex.) 20020101 |
| Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. | Cancer biology & therapy 20020101 |
| CHK and MEK inhibitors team up to trigger cancer cell suicide. | Cancer biology & therapy 20020101 |
| Independent antitumor spectrum of UCN-01 (7-hydroxystaurosporine) against gastric and colorectal cancers as detected by MTT assay. | Anticancer research 20020101 |
| Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. | Cancer biology & therapy 20020101 |
| Beyond directed therapeutics--are two drugs always better than one? | Cancer biology & therapy 20020101 |
| Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasma. | Journal of chromatography. B, Biomedical sciences and applications 20010905 |
| Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. | Neoplasia (New York, N.Y.) 20010901 |
| Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. | Cancer research 20010801 |
| Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. | Thyroid : official journal of the American Thyroid Association 20010801 |
| UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice. | International journal of oncology 20010701 |
| Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. | Cancer research 20010701 |
| Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010701 |
| UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. | Experimental hematology 20010601 |
| UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. | Japanese journal of cancer research : Gann 20010501 |
| Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415 |
| Regulation of the G2/M transition by p53. | Oncogene 20010405 |
| Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. | Oncogene 20010405 |
| Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. | International journal of oncology 20010401 |
| [CDK inhibitors for therapy of cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20010401 |
| UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010301 |
| S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. | Cancer research 20010201 |
| Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010201 |
| UCN-01 Kyowa Hakko Kogyo Co. | Current opinion in investigational drugs (London, England : 2000) 20010201 |
| Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? | The Journal of biological chemistry 20010105 |
| Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. | Leukemia 20010101 |
| Pharmacokinetics, distribution, metabolism and excretion of. | Cancer chemotherapy and pharmacology 20010101 |
| Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. | Anticancer research 20010101 |
| Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. | Anticancer research 20010101 |
| Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. | Blood 20000715 |
| The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. | Cancer research 20000415 |
| Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. | Biochemical pharmacology 19991201 |
| Analogs of staurosporine: potential anticancer drugs? | General pharmacology 19981101 |
| Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells. | The Journal of biological chemistry 19971212 |
| Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. | Molecular pharmacology 19940601 |
| Comparison of effects of protein kinase C inhibitors on phorbol ester-induced CD4 down-regulation and augmentation of human immunodeficiency virus replication in human T cell lines. | Biochemical and biophysical research communications 19891016 |
| Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. | Trends in pharmacological sciences 19890601 |
| UCN-01, a selective inhibitor of protein kinase C from Streptomyces. | The Journal of antibiotics 19871201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.